Sarcoma  >>  gemcitabine  >>  Phase 2
Welcome,         Profile    Billing    Logout  

30 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gemcitabine / Generic mfg.
NCT02511132: A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Completed
2b
22
US
Vigil, formerly known as FANG™, bi-shRNAfurin and GMCSF Autologous Tumor Cell Immunotherapy, Temozolomide, TEMODAR, Irinotecan, CAMPTOSAR, Gemcitabine, GEMZAR, Docetaxel, TAXOTERE
Gradalis, Inc.
Ewing's Sarcoma
11/18
12/20
NCT00556049: Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Checkmark ASCO-GU 2015
Feb 2015 - Feb 2015: ASCO-GU 2015
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
72
US
Gemcitabine, Gemzar, Sunitinib, Sutent
Massachusetts General Hospital, Pfizer, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute
Renal Cell Carcinoma, Neoplasm Metastases
12/13
12/14
NCT00887809: Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

Completed
2
47
US
gemcitabine, docetaxel, bevacizumab
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Sarcoma, Leiomyosarcoma, Malignant Fibrous, Histiocytoma, Angiosarcoma
10/14
11/14
NCT01574716 / 2012-001399-12: Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

Completed
2
209
Europe, US, RoW
MORAb-004, Gemcitabine, Docetaxel, Placebo
Morphotek
Metastatic Soft Tissue Sarcoma
08/15
08/16
NCT00496587: Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Completed
2
34
US
Capecitabine, Xeloda, Gemcitabine, Gemzar, Gemcitabine Hydrochloride, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF
M.D. Anderson Cancer Center, Eli Lilly and Company
Renal Cell Carcinoma, Kidney Cancer
05/16
05/16
2009-017261-32: Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma

Completed
2
90
Europe
Gemcitabine, Gemcitabine, Film-coated tablet, Concentrate for solution for infusion, Votrient 400 mg film-coated tablets, Votrient 200 mg film-coated tablets
Martin-Luther-Universität Halle-Wittenberg, GlaxoSmithKline GmbH & Co.KG, Aspen Bad Oldesloe GmbH, Martin Luther Universität Halle (Saale)
Relapsed or metastatic soft tissue sarcoma, Relapsed or metastatic soft tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT02448537: A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

Completed
2
42
US
PM01183, lurbinectedin, Doxorubicin, Hydroxydaunomycin Hydrochloride, Adriamycin, Hydroxydoxorubicin Hydrochloride, Gemcitabine, Gemzar
Massachusetts General Hospital, Dana-Farber Cancer Institute, PharmaMar
Metastatic Sarcoma
02/17
04/19
TAUL, NCT02249702 / 2009-016017-24: Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma

Completed
2
168
Europe
gemcitabine + docetaxel, Gemzar, Taxotere, trabectedin, Yondelis
Mario Negri Institute for Pharmacological Research, PharmaMar
Leiomyosarcoma
04/17
04/17
NCT01593748: A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Completed
2
90
US
Gemcitabine and Pazopanib, Gemcitabine and Docetaxel
Medical University of South Carolina, Novartis
Sarcoma
04/19
04/19
NCT01532687: Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Completed
2
54
US
Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Pazopanib, GW786034, Pazopanib Hydrochloride, GW786034B, Votrient, Placebo Administration
OHSU Knight Cancer Institute, Novartis Pharmaceuticals, Oregon Health and Science University
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated Pleomorphic Sarcoma, Malignant Adult Hemangiopericytoma, Recurrent Adult Soft Tissue Sarcoma, Sarcoma, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
10/19
10/19
2020-000741-13: Trial assessing the activity of TrabectedIn vs gemCitabine in patients with advanced LEiomyosarcoma Studio sull’attività della Trabectedina vs Gemcitabina in pazienti con leiomiosarcoma avanzato pretrattati c

Not yet recruiting
2
100
Europe
Trabectedina, Gemcitabina, [trabectedina], [Gemcitabina], Powder for infusion, Concentrate for solution for infusion, Yondelis, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 2 ML
ITALIAN SARCOMA GROUP, Pharmamar
metastatic or locally advanced Leiomyosarcoma pretreated with conventional chemotherapy leiomiosarcoma metastatico o localmente avanzato pretrattati con chemioterapia convenzionale, advanced Leiomyosarcoma leiomiosarcoma avanzato, Diseases [C] - Cancer [C04]
 
 
2018-003835-31: Targeting ATR in soft-tissue sarcomas: a randomized phase II study. TARSARC study Ciblage d’ATR dans les sarcomes des tissus mous : une étude randomisée de phase II. Etude TARSARC

Not yet recruiting
2
72
Europe
Berzosertib, GEMCITABINE, M6620, Solution for infusion, GEMCITABINE
Institut Bergonié, Merck Healthcare KGaA
Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas Léiomyosarcomes localement avancés et/ou métastatiques, Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas Léiomyosarcomes localement avancés et/ou métastatiques, Diseases [C] - Cancer [C04]
 
 
EAGLES, NCT03536780: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

Recruiting
2
38
RoW
Avelumab and Gemcitabine
Gachon University Gil Medical Center, Merck KGaA, Darmstadt, Germany, Chong Kun Dang Pharmaceutical Corp.
Leiomyosarcoma Metastatic
12/21
12/22
NCT04906876: A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Withdrawn
2
0
US
Gemcitabine, Docetaxel, 9-ING-41
Brown University, Actuate Therapeutics Inc.
Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, Spindle Cell Sarcoma, High Grade Sarcoma, Bone Sarcoma
07/22
07/25
NCT03912818: Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Terminated
2
7
US
Carboplatin, Carboplat, Carboplatino, Carbosol, Paraplatin, Paraplatine, Cisplatin, Abiplatin, Briplatin, Cis-platinum, Cismaplat, Citoplatino, Plastistil, Platinol, Cystectomy, Doxorubicin, Adriablastin, Hydroxyl Daunorubicin, Rubex, Durvalumab, Imfinzi, MEDI-4736, Gemcitabine, Difluorodeoxycytidine, Gemzar, Methotrexate, Abitrexate, Amethopterin, Brimexate, Methotrexate Methylaminopterin, Metotrexato, Vinblastine, Vincaleucoblastine, Vinblastine Sulfate, vincaleukoblastine, sulfate
Stanford University, AstraZeneca
Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
08/22
08/22
NCT02203760 / 2012-003810-15: Pazopanib vs. Pazopanib Plus Gemcitabine

Active, not recruiting
2
58
Europe
Pazopanib plus Gemcitabine, Votrient and Gemzar, Pazopanib, Votrient
North Eastern German Society of Gynaecological Oncology, Novartis Pharmaceuticals, medac GmbH
Leiomyosarcoma or Carcinosarcoma
12/24
12/24
NCT05481645: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Recruiting
2
79
RoW
TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Paclitaxel Injection, Doxorubicin Hydrochloride Injection, Gemcitabine Hydrochloride Injection, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer, Sarcoma of Uterus
06/24
12/24
ISG-ARTICLE, NCT04383119: Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting
2
100
Europe
Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort
Italian Sarcoma Group, PharmaMar
Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
06/24
09/24
Actuate 1801, NCT03678883: 9-ING-41 in Patients With Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc.
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
11/24
11/25
GemTax, NCT01879085: Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma

Completed
1b/2
37
US
Docetaxel, Taxotere, Gemcitabine, Gemzar, Vorinostat, Zolinza, Pegfilgrastim, Neulasta
Melissa Burgess, MD, Merck Sharp & Dohme LLC
Sarcoma
04/21
04/21
NCT01491594: Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

Terminated
1/2
1
US
Eltrombopag, Promacta
Duke University, GlaxoSmithKline
Sarcoma, Soft Tissue, Osteosarcoma, Neoplasms, Connective and Soft Tissue
03/13
03/13
NCT01719302: Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Completed
1/2
6
US
Gemcitabine, Gemzar, Docetaxel, Taxotere, Pazopanib, Votrient
University of Vermont, Novartis
Stage III Adult Soft Tissue Sarcoma
04/15
04/15
NCT03009058 / 2016-001459-28: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated
1/2
2
Europe
IMM-101, Heat killed M. obuense (NCTC) 13365), Gemcitabine, GEMZAR, Nabpaclitaxel, Abraxane, Capecitabine, Folinic Acid, Leucovorin, Fluorouracil, 5FU, Irinotecan, Campto, Camptosar, Oxaliplatin, Eloxatin, cetuximab, Erbitux, Anti-PD1, pembrolizumab (KEYTRUDA),, nivolumab (OPDIVO), Ipilimumab, YERVOY, Cyclophosphamide, cytophosphane
Immodulon Therapeutics Ltd
Metastatic Cancer
08/17
08/17
NCT03684811: A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Completed
1/2
93
Europe, US, RoW
FT-2102, Azacitidine, Vidaza, Nivolumab, Opdivo, Gemcitabine and Cisplatin, Gemzar and Platinol
Forma Therapeutics, Inc.
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
05/21
06/22
GEMMK, NCT03123276: Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma

Active, not recruiting
1/2
24
Europe
Pembrolizumab, Keytruda, Gemcitabine
Royal Marsden NHS Foundation Trust, Merck Sharp & Dohme LLC
Sarcoma
02/23
02/23
NCT04145700 / 2018-004243-23: CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Terminated
1/2
23
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Gemcitabine, Docetaxel
Eli Lilly and Company
Synovial Sarcoma
02/23
02/23
NCT05093322 / 2021-003602-41: A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Completed
1/2
13
US
Surufatinib in combination with Gemcitabine, HMPL-012, sulfatinib in combination with Gemcitabine
Hutchmed, HUTCHMED Limited
Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
04/23
04/23
ZN-c3-003, NCT04833582 / 2021-000021-27: A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma

Active, not recruiting
1/2
84
Europe, US
ZN-c3, Gemcitabine, Gemzar
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Osteosarcoma
08/23
12/23
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
NCT04577014: Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Active, not recruiting
1/2
67
US
Retifanlimab, INCMGA00012, Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
09/25
09/25

Download Options